Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer.
about
Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain.Effects of aprepitant on the pharmacokinetics of controlled-release oral oxycodone in cancer patients.Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children.Analgesic efficacy of controlled-release oxycodone in postoperative pain.Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients.Design and in vivo evaluation of oxycodone once-a-day controlled-release tabletsMetabolism of oxycodone in human hepatocytes from different age groups and prediction of hepatic plasma clearance.Effects of repeated oxycodone administration on its analgesic and subjective effects in normal, healthy volunteers.Present-day challenges and future solutions in postoperative pain management: results from PainForum 2014.Pharmacokinetics of morphine and oxycodone following intravenous administration in elderly patients.Oxycodone/paracetamol: a low-dose synergic combination useful in different types of pain.Perspectives on Intravenous Oxycodone for Control of Postoperative Pain.Retrospective Evaluation of a Fixed-Dose Combination of Oxycodone and Acetaminophen to Manage Moderate Pain: The Lower the Better.Population pharmacokinetics of oxycodone in patients with cancer-related pain.Successful dose finding with sublingual fentanyl tablet: combined results from 2 open-label titration studies.Oral versus intravenous opioid dosing for the initial treatment of acute musculoskeletal pain in the emergency department.Morphine or oxycodone in cancer pain?Prescription Opioids. V. Metabolism and Excretion of Oxymorphone in Urine Following Controlled Single Dose Administration.Extemporaneous compounding of pain and symptom control medications.Prescription opioids. III. Disposition of oxycodone in oral fluid and blood following controlled single-dose administration.Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients.Comparison of the pharmacokinetics of oxycodone administered in three Percocet formulations.Dynamics of breakthrough pain vs. pharmacokinetics of oral morphine: implications for management.Plasma concentrations of oral oxycodone are greatly increased in the elderly.Observations of urinary oxycodone and metabolite distributions in pain patients.Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients.Contribution of oxycodone and its metabolites to the overall analgesic effect after oxycodone administration.Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy.Hydrocodone is More Effective than Morphine or Oxycodone in Suppressing the Development of Burn-Induced Mechanical Allodynia.Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.Liposolubility and protein binding of oxycodone in vitro.Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose.Hydrocodone, but Neither Morphine nor Oxycodone, Is Effective in Suppressing Burn-Induced Mechanical Allodynia in the Uninjured Foot Contralateral to the Burn.
P2860
Q33520508-5B5D6699-E8B1-40B0-9B82-2DADA7FEF421Q34046633-6CDD9811-9CF9-4D1E-9A0C-24C6413501A2Q34346502-8A9308B1-D3AC-4C63-BB7C-ED2485758F2BQ34400847-3F4076D0-A761-4CCA-9D0A-667C2499A52EQ34792547-4FA0F7E0-5F69-4C95-8532-42297E92F819Q35066646-8305190F-433D-447B-91C1-372875E28F93Q35653564-2EF3E570-C0A4-45C9-9C5B-590D50C328A2Q35927404-87FB2AB5-0288-4F5F-BC66-F1984E5D2BD1Q36557969-0B837961-3DBF-4801-B1AE-1CF635BAB657Q36645757-8C9D260C-F43A-4AFD-AA02-E1DB1465C1F8Q37776491-62B93A38-E5E8-42F2-8251-2BD82E3A694BQ38590899-5A494811-8582-42DB-867C-B6DB98907A61Q39173147-E96D8331-C91B-4767-8DAC-998584E96AC6Q39241949-99E3580F-8009-48E7-991C-88B5F26B0EBBQ39253677-318186AE-51DE-4C1E-A364-A00ED1D310FDQ39312895-855C3916-645B-4BB7-A99E-6DEE41F63B4BQ39421912-ABE50BE4-04A8-4F4D-AE03-F407B0F12EA5Q39609516-6EA618A5-E93C-460E-BD50-881AE6540ADEQ40547477-05C1CB84-79BA-42F9-A8C7-C9BF04CEE5C6Q41581475-0724D534-D03D-4B65-9D8D-A53A73ACE5BCQ43244977-55AB5DAF-9BC9-4B50-A9D7-613D0CDBC94DQ43613480-1F4522AA-48C7-43AD-AD7B-691BB9C0E9B7Q43878868-97A77392-563D-452E-9FD4-841E2899EDB6Q45994501-266E0C1A-B1BE-4A04-83F9-9F8D6077D934Q46111555-F79C4F9B-6674-46FC-B065-CE9A2385CC4DQ46121183-70BA3DD4-6B09-4791-9EA7-C30A1292820FQ48043695-62839C65-3BB9-4F67-B293-E4FF118BFFA2Q48127325-B2EBC3EA-05C1-42EB-90C8-D4A4E5414824Q48174953-4E76035F-2551-4FEB-80E9-8DE2D4E573B2Q50775719-23E52569-FFFE-4A25-BB83-E29E654E6F6EQ51112914-77A105E0-A74E-4526-A742-0193D3893DC7Q51644378-4915A979-019C-45A5-901A-B4BCBBF93450Q52317280-9BD15B2D-6636-483F-BD63-9CA0C945380BQ53641920-D656617D-F41C-4333-9F03-91F1B7272113
P2860
Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
Single-dose and steady-state p ...... odone in patients with cancer.
@en
Single-dose and steady-state p ...... odone in patients with cancer.
@nl
type
label
Single-dose and steady-state p ...... odone in patients with cancer.
@en
Single-dose and steady-state p ...... odone in patients with cancer.
@nl
prefLabel
Single-dose and steady-state p ...... odone in patients with cancer.
@en
Single-dose and steady-state p ...... odone in patients with cancer.
@nl
P2093
P356
P1476
Single-dose and steady-state p ...... odone in patients with cancer.
@en
P2093
P2888
P304
P356
10.1038/CLPT.1992.176
P407
P577
1992-11-01T00:00:00Z
P5875
P6179
1022730537